Nucleic Acid News and Research

RSS

WHO endorses new rapid fully automated nucleic acid amplification test for TB

Today, WHO endorsed a new and novel rapid test for tuberculosis (TB), especially relevant in countries most affected by the disease. The test could revolutionize TB care and control by providing an accurate diagnosis for many patients in about 100 minutes, compared to current tests that can take up to three months to have results.

8 Dec 2010

IRIS announces product acquisition from BioMicro Systems

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that it has acquired the assets of a multi-purpose, bench-top instrument platform for automating highly repetitive, manual laboratory protocols for (F)ISH (fluorescence in-situ hybridization) testing and other slide-based cytogenetic applications.

30 Nov 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. "These molecules can interact with the estrogen hormone and, thus, even lead to cancer," explains Dr. Joerg Hoheisel; molecular biologist at DKFZ. "The connection between the levels of the estrogen receptor alpha and the occurrence of breast cancer has been known for some time now.

24 Nov 2010

USPTO, EPO issue key patents for Tekmira's LNP technology

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).

23 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

PubDNA Finder search engine links biomedical articles to nucleic acid sequences

Researchers from the Universidad Politécnica de Madrid's Biomedical Informatics Group based at the Facultad de Informática have created a tool called PubDNA Finder. This tool is the first search engine specialized in linking biomedical articles to nucleic acid sequences.

16 Nov 2010

GenturaDx to showcase IDbox molecular diagnostic system at AMP 2010

GenturaDx will display its proprietary molecular diagnostic system, the IDbox System, at the annual meeting of the Association for Molecular Pathology (AMP) in San Jose, Calif. on November 17 – 20, 2010. The IDbox System incorporates all aspects of its proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette.

15 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

New Ovation systems improve nucleic acid extraction from FFPE tissue samples

NuGEN Technologies, the provider of innovative RNA and DNA sample preparation solutions for genomic analysis, today announced the availability of the Ovation WGA FFPE System and the Ovation RNA-Seq FFPE System. These are the first commercially available products designed specifically to enable researchers to utilize next-generation sequencing (NGS) technologies to analyze nucleic acids extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

3 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command's Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.

19 Oct 2010

New, affordable technology for cervical cancer screening

Current cervical cancer screening is time consuming and expensive, but now new breakthrough technology developed by European researchers should allow large-range screening by non-medical personnel with almost immediate results and at a much lower cost.

15 Oct 2010

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.

14 Oct 2010

Exiqon introduces on-line microRNA qPCR assay design software

Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.

12 Oct 2010

cobas TaqScreen DPX Test now available with CE Mark: Roche

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay.

5 Oct 2010

Covaris enters co-marketing partnership with Illumina for DNA shearing technologies

Covaris Inc. today announced that it has signed a co-marketing agreement with Illumina, Inc. making Covaris DNA shearing technologies the recommended method of shearing with Illumina next-generation sequencing product lines, including HiSeq, HiScanSQ, and Genome Analyzer.

From Illumina, Inc. 29 Sep 2010

Researchers identify biomarkers for mesothelioma and pancreatic cancer

Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer, pancreatic and mesothelioma.

29 Sep 2010